Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tofimilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 16/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 16/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 16/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 15/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tofimilast SCHEMBL4914697 | 0.93 | PDE4A (0.86) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL6839751 | 0.84 | PDE4A (0.79) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL13111733 | 0.83 | PDE4A (0.70) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL6358572 | 0.80 | PDE4A (1.00) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL6052681 | 0.80 | PDE4A (0.66) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL210263 | 0.76 | PDE4A (1.00) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| Tofimilast SCHEMBL3676458 | 0.75 | PDE4B (0.56) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| Tofimilast SCHEMBL3676455 | 0.75 | PDE4B (0.56) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL84865 | 0.69 | PDE4A (1.00) | PDE4APDE4BPDE4DADORA3ADORA2A | |
| SCHEMBL14455896 | 0.68 | PDE4A (0.84) | PDE4APDE4BPDE4DADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-11504332-B2 | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof | VK RESEARCH ASSOCIATES INC. (US) | 2022-11-22 | — | — | US | claimed |
| US-20220304935-A1 | PHOSPHODIESTERASE-4 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2022-09-29 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-2858649-B1 | TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS | PSYCHOGENICS INC (US) | 2019-10-23 | — | — | EP | claimed |
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| EP-1397135-A2 | COMBINATION OF A PDE4 INHIBITOR AND TIOTROPIUM OR DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-03-17 | — | — | EP | claimed |
| EP-1395288-A1 | A PDE 4 INHIBITOR AND AN ANTI-CHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2004-03-10 | — | — | EP | claimed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030064031-A1 | For therapy of respiratory diseases such as asthma or chronic obstructive pulmonary disease | PFIZER INC. | 2003-04-03 | — | — | US | claimed |
| WO-2002096423-A2 | COMBINATION OF A PDE4 INHIBITOR AND TIOTROPIUM OR DERIVATE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096463-A1 | A PDE 4 INHIBITOR AND AN ANTI-CHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | claimed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | claimed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE12, PDE3A, PDE3B | PDE4A 6/4885PDE4B 5/4885PDE4D 15/4885 |
| US-20030064031-A1 | For therapy of respiratory diseases such as asthma or chronic obstructive pulmonary disease | TMCO1, CHRM3, IL5 | PDE4A 108/4885PDE4B 135/4885PDE4D 172/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4D 1677/4885 |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | ADH1A, ADH1C, OTC | PDE4A 1915/4885PDE4B 2742/4885PDE4D 3155/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4D 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.